COMPANY
GENECKER’S HISTORY
Standardization of liquid-biopsy diagnosis
based on ultra-precision CRISPR/Cas9 technology
“Our ultra-precision cancer diagnosis service will provide a new paradigm shift in early
cancer detection with a technology that can selectively analyze a slight amount of cancer
genes in the blood.”
Chief Executive Officer 
CEO/CTO & Co-Founder
“It all began with a simple wish—to protect those I love most.”
Seonghyeok Ye, co-founder and co-CEO of GeneCker, is a genome engineering specialist who pioneered the world’s first commercial precision ctDNA detection platform based on CRISPR technology. His journey began with a sincere desire to protect his own family from cancer, a mission deeply embedded in every technology and service offered by GeneCker today.
With expertise in genome engineering gained from IBS School–UST, Ye has focused on translating groundbreaking research into practical diagnostic solutions. He developed an ultra-sensitive genomic analysis platform capable of accurately detecting even extremely low-frequency cancer mutations, significantly improving both the accuracy and speed of cancer diagnosis.
Driven by the goal of becoming a company that reaches out first when someone faces their most challenging moments, Ye continues to create technologies designed truly for the benefit of people.
CEO/CMO & Co-Founder
Junseok W. Hur is the Co-Founder and Co-CEO of GeneCker. He also serves as the Professor of Neurosurgery at Korea University College of Medicine and as the Director of the Precision Medicine Research Center at Korea University Anam Hospital. Inspired by the completion of the Human Genome Project during his medical training, Dr. Hur has dedicated his career to advancing the field of precision medicine.
While balancing his dual roles as a clinician and researcher at a university hospital, he led the world’s first successful integration of CRISPR genome-editing technology into liquid biopsy-based cancer diagnostics. Recognizing the inherent limits of clinical practice, Dr. Hur co-founded GeneCker with a clear mission: to develop innovative diagnostic technologies capable of transforming patient care on a global scale.
VP of Strategy
Kyung-Hak Choi is the VP of GeneCker, responsible for defining and executing the company’s overall strategic direction. Drawn by the transformative potential at the intersection of proprietary CRISPR/Cas technology and advanced liquid biopsy platforms, Dr. Choi joined GeneCker with a vision to help shape the future of cancer diagnostics.
Prior to joining GeneCker, Dr. Choi served as Director of R&D at Noul and as Chief Technology Officer at Optolane, where he built deep expertise in the field of in vitro diagnostics (IVD). Dr. Choi holds a Ph.D. in Electrical Engineering from The University of Texas at Dallas and earned his bachelor’s degree in Electrical Engineering from Seoul National University. With a background spanning from the semiconductor industry to next-generation diagnostic technologies, he brings to GeneCker a rare combination of engineering rigor and translational insight.
VP of R&D
In-Seon Lee leads the Product Development Team and the Molecular Diagnostics Laboratory at GeneCker. She earned her undergraduate degree in Genetic Engineering from Kyung Hee University and completed her M.S. and Ph.D. at Chung-Ang University, where she focused on the molecular mechanisms of cancer and cellular signal transduction networks.
Prior to joining GeneCker, Dr. Lee gained extensive experience in the development and clinical implementation of cancer diagnostic products at companies specializing in companion diagnostics and cancer genomics. Her current work centers on the development of ultra-sensitive genetic testing technologies capable of precisely detecting even trace amounts of genetic mutations and translating them into clinically actionable information.
She is committed to transforming complex genomic signals into optimized diagnostic solutions that capture the full potential of molecular data.
GENECKER’S VISION
Popularization of cancer diagnosis
